When Clear Vision Is Not Enough A Case for Preventive Optometry

Introduction

A patient presenting with blurred vision may appear to have a straightforward refractive problem. Yet one of the most important responsibilities of an optometrist is not simply to determine what prescription improves vision, but to understand why vision is no longer as good as expected.

This distinction becomes increasingly important with age. Refractive change may coexist with cataract, glaucoma, retinal disease or other ocular conditions, while systemic health, smoking, diet and lifestyle may influence longer-term ocular risk.

The following case began with a familiar complaint: a patient who remained dissatisfied with his vision despite having obtained new spectacles only six months earlier. What followed raises a broader question for optometric practice:

Is our role primarily to correct vision and detect existing disease, or should optometry also take a more structured role in recognising and addressing risk before significant visual impairment develops?

Age-related macular degeneration (AMD) provides an important example. Nutritional and lifestyle discussions often become more structured once retinal changes are present. The Age-Related Eye Disease Study (AREDS) and AREDS2 established an important role for nutritional supplementation in selected patients at risk of AMD progression.^1–3 However, AREDS2 was not designed to demonstrate that supplementation prevents AMD in individuals without disease.

This leaves an important clinical space between apparently healthy ageing and established disease. It is within this space that preventive optometry may have an increasingly important role.

The Case

A 65-year-old man presented with progressively deteriorating distance vision. He described having to “struggle” to see clearly at distance and had become increasingly frustrated by the quality of his vision.

His medical history included hypertension treated with once-daily medication and a history of smoking. No other significant systemic conditions were reported.

Approximately six months earlier, he had obtained new spectacles from a high-volume optical retailer. According to the patient, the consultation had primarily involved refraction and spectacle dispensing, without a comprehensive ocular health examination.

This should not simply be viewed as criticism of a particular optical business model. From the perspective of the general public, the distinction between refraction and a comprehensive eye examination may not always be understood. A consumer may reasonably assume that having their prescription checked means that their eyes have also been examined. Similarly, many patients may not fully appreciate the broader clinical scope of optometric practice, including ocular health assessment, identification of retinal and anterior segment abnormalities, risk assessment, monitoring and appropriate referral.

Despite wearing his new spectacles, his visual difficulties gradually increased. Initially, he accepted the deterioration and continued with the spectacles. Eventually, the increasing difficulty prompted him to seek another assessment.

Clinical examination revealed moderate myopia with mild astigmatism and presbyopia. Near visual acuity reached N5. Bilateral grade 2 nuclear sclerotic lens changes were present. Amsler grid testing did not reveal subjective metamorphopsia in either eye. However, retinal examination and fundus photography demonstrated macular and para-macular changes with drusen-like deposits surrounding the central retinal region.

A 6-mm macular scan obtained using the swept-source OCT function incorporated within the axial-length device provided additional structural information. The outer retinal/RPE contour appeared irregular in areas corresponding to the retinal changes, with localised undulation of the outer retinal complex. Given the resolution and segmentation limitations of this imaging system, subtle ellipsoid-zone disruption could not be established confidently and would require confirmation with higher-resolution diagnostic macular OCT.

Taken together, the findings indicated that the patient's visual complaint could not simply be considered a refractive problem. Appropriate counselling regarding the retinal findings, further ophthalmic assessment and continued retinal monitoring were therefore indicated.

Yet the significance of the case extends beyond detecting retinal abnormality. It asks whether opportunities to recognise and address risk may have existed before structural retinal changes became clinically apparent.

Refraction Is Not Comprehensive Eye Care

Refraction answers an important clinical question: What optical correction provides the clearest achievable vision?

A comprehensive eye examination asks something broader: Why is this patient seeing the way he is?

The distinction matters.

A patient may receive an accurate spectacle prescription while simultaneously having cataract, glaucoma, diabetic retinal disease, AMD or another ocular condition affecting visual performance. Spectacles correct refractive error. They do not explain progressive visual deterioration. The concern is therefore not where spectacles are purchased, nor whether rapid optical services should exist. Such services can provide convenience and accessibility.

The larger issue is whether the public understands the difference between having vision corrected and having the eyes examined.

If the two become interchangeable in the patient's mind, the clinical role of optometry risks becoming similarly blurred. But even comprehensive examination represents only part of the opportunity. Finding disease earlier is important.

Detection, however, is not necessarily prevention.

From Correction to Detection to Prevention

Three overlapping roles can be considered in contemporary optometric care:

Correction addresses an existing visual problem. Refraction, spectacles and contact lenses are obvious examples.

Detection identifies pathology that may already be present. Retinal examination, OCT and other clinical investigations allow optometrists to recognise abnormalities that patients themselves may not yet appreciate.

Prevention asks another question:

What factors present today may influence this patient's ocular health tomorrow, and which of them can reasonably be modified?

In AMD, several important risk factors cannot be changed, including increasing age and genetic susceptibility. Smoking, however, is one of the strongest established modifiable risk factors for AMD.⁴ Hypertension and other cardiovascular factors have also been associated with AMD, while dietary patterns may influence long-term retinal health.^5–8

The patient described here therefore presented with more than retinal findings.

• His smoking history mattered.
• His systemic health mattered.
• His diet and nutritional status may have mattered.
• And his retinal appearance mattered.

Preventive optometry should therefore not simply mean performing more tests. Its value lies in connecting examination findings with risk and determining whether modifiable factors can reasonably be addressed.

The Preventive Optometry Gap

Clinical eye care is understandably strongest where evidence is clearest. As disease becomes established, diagnostic criteria, referral pathways and management guidelines become increasingly defined. Before that point, the situation is less structured.

Consider the AMD continuum:

At the later stages, management becomes progressively more specific. Earlier in the continuum, advice may remain comparatively general:

• Don't smoke.
• Eat healthily.
• Exercise.
• Have your eyes examined regularly.

These are sensible recommendations. The difficulty is that they are often delivered without the same structured risk assessment that occurs once pathology is established.

This creates what we propose as a Preventive Optometry Gap: the clinical space between the absence of disease-specific treatment and the point at which pathology has developed sufficiently for established management pathways to apply.

The gap should not automatically be filled with more testing or supplementation. Rather, it represents an opportunity for:

Nutrition sits within this pathway, but it is only one component.

When Should the Nutritional Conversation Begin?

Perhaps one of the most practical questions for optometrists is:

When should I start discussing retinal nutrition with my patient?

The answer may be simpler than it initially appears.

The nutritional conversation can begin before disease. Disease-specific supplementation does not necessarily need to.

These two concepts should not be confused. An optometrist does not need to wait until drusen appear before asking whether a patient smokes, what their general dietary pattern looks like, or whether systemic health is being appropriately managed.

Likewise, discussing carotenoid-rich foods, fish, vegetables, fruit, nuts and an overall healthy dietary pattern does not mean that the clinician is treating AMD in a patient who does not have AMD.

Observational evidence supports this broader dietary perspective. Greater adherence to Mediterranean-style dietary patterns has been associated with a lower risk of progression to advanced AMD and lower incidence of advanced AMD in prospective cohort analyses.^6,7 Higher dietary intakes of several nutrients have also been associated with different trajectories of AMD progression in analyses of AREDS and AREDS2 populations.⁸

These associations do not prove that a particular diet will prevent AMD in an individual patient. Nevertheless, they provide a reasonable basis for discussing dietary quality as part of overall ocular and systemic health.

The challenge begins when the conversation moves from food to supplementation.

Where Does Precision Visual Nutrition Fit?

Huang recently proposed Precision Visual Nutrition (PVN) as an approach to individualising ocular nutritional management rather than assuming that the same formulation is appropriate for every patient.⁹ That framework has been discussed previously and need not be reproduced here.

Instead, the present case asks a related but broader question: Where should nutritional reasoning sit within preventive optometric care?

Within preventive optometry, nutrition should be considered alongside smoking, systemic health, lifestyle, ocular findings and other relevant factors. This distinction may make nutritional conversations more comfortable for optometrists. The clinician does not need to begin by asking: Which supplement should I prescribe?

Is there anything about this patient's diet, lifestyle or systemic health that may reasonably be addressed in support of long-term ocular health?

Supplementation becomes a subsequent consideration rather than the starting point.

Lutein Is Important — but It Is Not the Whole Story

When ocular nutrition is discussed with patients, the conversation frequently becomes centred on one ingredient: lutein. This risks oversimplifying macular carotenoid biology.

The human macular pigment contains three principal xanthophyll carotenoids: lutein, zeaxanthin and meso-zeaxanthin. A systematic review and meta-analysis examining lutein/zeaxanthin intake and macular pigment optical density (MPOD) in healthy adults reinforces that macular pigment should not be considered a lutein-only system.¹⁰

Zeaxanthin deserves particular attention because its retinal distribution differs from that of lutein, with a greater relative concentration centrally within the macula. The two carotenoids therefore should not simply be regarded as interchangeable ingredients.

This is also reflected in AREDS2. The carotenoid intervention was not lutein alone. Participants received 10 mg lutein together with 2 mg zeaxanthin.²

However, this should not lead to another oversimplification. The familiar 10:2 combination represents a dose studied within a defined AREDS2 population at high risk of progression to advanced AMD. It does not establish that every healthy adult requires 10 mg lutein and 2 mg zeaxanthin, nor does it establish that this ratio is a universal biological optimum.

Evidence in adults with healthy eyes indicates that lutein/zeaxanthin intake can increase MPOD, although responses vary and the minimum clinically important dose and duration remain uncertain.¹⁰

Increasing macular pigment is not the same as proving prevention of AMD.

A biomarker response should not automatically be translated into a disease-prevention claim.

When Should an Optometrist Recommend Supplementation?

Rather than creating a rigid prescribing guideline unsupported by current evidence, a practical three-level approach may help clinicians distinguish nutritional counselling from disease-specific supplementation.

The practical distinction is therefore:

• Before disease: discuss nutrition and optimise risk.
• With increased risk or early changes: individualise, consider and monitor.
• At appropriate AMD stages: follow disease-specific evidence.

If We Recommend Supplements, Do We Understand What We Are Recommending?

For optometrists to become comfortable discussing supplementation, confidence should come from understanding the evidence — not from becoming supplement salespeople. Three questions are useful:

• What is in the formulation?
• Why am I recommending it?
• Is it appropriate for this patient?

The present patient's smoking history demonstrates why this matters. The original AREDS formulation contained beta-carotene. In AREDS2, more lung cancers occurred among participants assigned to beta-carotene than those not receiving beta-carotene, with most cases occurring among former smokers.² Ten-year follow-up continued to demonstrate an increased lung-cancer risk among those originally assigned beta-carotene, whereas this increase was not observed with lutein/zeaxanthin.¹¹

A current or former smoker should therefore not simply be told to purchase an unspecified “eye vitamin.” The actual formulation matters.

Safety also extends beyond smoking history. Lutein generally has a favourable safety profile, but the assumption that a nutrient is natural does not mean that dose and source are irrelevant. The European Food Safety Authority established an acceptable daily intake (ADI) of 1 mg/kg body weight/day for specified lutein preparations derived from Tagetes erecta. Importantly, EFSA cautioned that the available toxicological evidence was insufficient to automatically extend this ADI to lower-purity lutein preparations or preparations from other sources.^12,13

An ADI should also not be confused with a recommended ocular dose. It is a toxicological safety boundary, not a target for supplementation.

Studied clinical dose ≠ recommended general-health dose ≠ safety threshold.

Returning to Our Patient: Should We Have Acted Before Disease?

It is tempting to look at this 65-year-old patient retrospectively and ask: If he had taken lutein and zeaxanthin ten years ago, would his retinal findings have been prevented?

We cannot answer that question. Current evidence does not justify telling patients that lutein/zeaxanthin supplementation will prevent AMD. But perhaps that is not the most useful question.

Imagine that this patient had presented five or ten years earlier, before obvious macular changes were present.

• His smoking history could have been identified.
• His hypertension could have been recognised as part of his systemic-health context.
• His dietary pattern could have been discussed.
• His retinal appearance could have been documented as a baseline.
• His family history and other relevant risks could have been explored.
• Appropriate dietary advice could have been provided.
• And his ocular health could have been followed longitudinally.

None of this requires claiming that AMD could have been prevented. It simply means that preventive care begins before disease becomes the reason for having the conversation.

Should we really wait for drusen before asking our patients what they eat?

Making Preventive Nutrition Practical for Optometrists

Optometrists may sometimes hesitate to discuss nutrition because they feel that recommending supplements moves outside familiar territory. A simpler approach is to separate nutritional counselling from supplement prescribing. For most patients, the conversation can begin with three questions:

What risks are present? Smoking, systemic health, family history and ocular findings provide context.

What is the patient's diet actually like? A recommendation to “eat more vegetables” is less useful than understanding whether the patient regularly consumes leafy green vegetables, colourful fruits and vegetables, fish, nuts and other nutrient-dense foods.

Is there a reason to go beyond dietary advice? Only then should supplementation become a consideration.

This approach allows optometrists to remain evidence-informed without feeling that every nutritional discussion must end with a bottle of supplements. It also shifts the professional role away from product recommendation and towards clinical reasoning.

Preventive Optometry Begins With Examination — but Does Not End There

The patient in this case initially wanted one thing: clearer vision. Refraction was necessary. But refraction alone was not enough.

His continuing symptoms required ocular examination, and the examination identified changes requiring further attention. Yet detection should not necessarily represent the endpoint of optometric care either.

A comprehensive examination provides an opportunity to understand not only what pathology exists today, but also what factors may influence ocular health tomorrow. This leads to a broader pathway:

Within that pathway, nutrition represents one modifiable domain alongside smoking, systemic health and lifestyle. Precision Visual Nutrition provides a framework for individualising that nutritional component.⁹ Preventive optometry provides the broader clinical context in which such reasoning can occur.

Conclusion

Optometry should not be defined solely by how accurately refractive correction can be provided. Its clinical value lies in understanding the patient behind the refractive error.

The 65-year-old man in this case did not simply need another pair of spectacles. His deteriorating vision required someone to ask why his vision was changing. But his case also raises an earlier question:

Are we recognising modifiable ocular-health risks soon enough?

Preventive optometry does not mean universal supplementation or attempting to treat disease before it exists. It means recognising that conversations about smoking, systemic health, diet and nutrition can begin before disease is established, while any intervention should remain individualised and evidence-informed.

We cannot know whether earlier intervention would have prevented this patient's retinal changes. But we can recognise opportunities to address modifiable risks before disease becomes the reason for doing so.

Perhaps the evolving role of optometry is therefore not only to correct vision and detect disease, but also to recognise risk earlier — helping patients see better today while protecting how they may see tomorrow.

Dr. Alex Ong, DOptom, FAAO, FOWNS, CPNP (US)

Optometrist, Singapore · PGCert (Anterior Eye Diseases, Cataract and Glaucoma) · PGCert (Retinal Disease Recognition and Co-Management) · MSCO, B.Sc Optom, Dip. Optom

Dr. Ong is the Founder and Managing Director/Optometrist at Ong's Optics Myopia Management Centre, established in 2005, and second-generation owner of Ong's Optics and Contact Lens Centre, established in 1985. With over two decades of clinical experience, his expertise spans evidence-based myopia management, ocular nutrition, binocular vision, orthokeratology, and geriatric vision care. He serves as a Key Opinion Leader for Menicon Japan and has taught as an adjunct lecturer at both optometry schools in Singapore. Dr. Ong is actively involved in optometric education and professional training across Asia. As a Certified Personalized Nutrition Practitioner (CPNP) with the American Nutrition Association, he integrates nutritional science with vision care to promote a proactive and preventive model of lifelong eye health. He is also a member and fellow of the American Academy of Optometry (AAO) and the Ocular Wellness and Nutrition Society (OWNS).